The population density of Bismarck, ND was 2,326 in 2018.
Population Density
Population Density is computed by dividing the total population by Land Area Per Square Mile.
Above charts are based on data from the U.S. Census American Community Survey | ODN Dataset | API -
Geographic and Population Datasets Involving Bismarck, ND
- API
Rates of COVID-19 Cases or Deaths by Age Group and Vaccination Status
data.cdc.gov | Last Updated 2022-06-30T19:01:32.000ZData for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes Webpage: https://covid.cdc.gov/covid-data-tracker/#rates-by-vaccine-status Dataset and data visualization details: These data were posted on June 17, 2022, and reflect cases among persons with a positive specimen collection date through May 21, 2022, and deaths among persons with a positive specimen collection date through April 30, 2022. These data will be updated monthly. Please note that these provisional data are subject to change. Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, Seattle King County (Washington), South Dakota, Tennessee, Texas, Utah, West Virginia and Wisconsin; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 70% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases among people who received additional or booste
- API
Incidence Of Brain And Central Nervous System Cancer Age 15 Under Per 1,000,000 All States
opendata.utah.gov | Last Updated 2019-04-19T01:42:51.000ZIncidence Of Brain And Central Nervous System Cancer Age 15 Under Per 1,000,000 All States
- API
NYCHA Development Data Book
data.cityofnewyork.us | Last Updated 2020-02-08T01:20:25.000ZContains the main body of the “Development Data Book” as of January 1, 2019. The Development Data Book lists all of the Authority's Developments alphabetically and includes information on the development identification numbers, program and construction type, number of apartments and rental rooms, population, number of buildings and stories, street boundaries, and political districts.
- API
Incidence Rate Of Pancreatic Cancer Per 100,000 All States
opendata.utah.gov | Last Updated 2019-04-19T06:47:25.000ZIncidence Rate Of Pancreatic Cancer Per 100,000 All States
- API
Incidence Rate Of Leukemia Per 100,000 All States
opendata.utah.gov | Last Updated 2019-04-19T00:30:16.000ZIncidence Rate Of Leukemia Per 100,000 All States
- API
Rates of COVID-19 Cases or Deaths by Age Group and Vaccination Status and Booster Dose
data.cdc.gov | Last Updated 2022-06-30T19:03:16.000ZData for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes Webpage: https://covid.cdc.gov/covid-data-tracker/#rates-by-vaccine-status Dataset and data visualization details: These data were posted on June 17, 2022, and reflect cases among persons with a positive specimen collection date through May 21, 2022, and deaths among persons with a positive specimen collection date through April 30, 2022. These data will be updated monthly. Please note that these provisional data are subject to change. Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, Seattle King County (Washington), South Dakota, Tennessee, Texas, Utah, West Virginia and Wisconsin; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 70% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases among people who received additional or booster
- API
Incidence Rate Of Mesothelioma Per 100,000 All States
opendata.utah.gov | Last Updated 2019-04-19T05:29:37.000ZIncidence Rate Of Mesothelioma Per 100,000 All States
- API
Incidence Rate Of Larynx Cancer Per 100,000 All States
opendata.utah.gov | Last Updated 2019-04-19T07:50:56.000ZIncidence Rate Of Larynx Cancer Per 100,000 All States
- API
Rates Of Esophageal Cancer Per 100,000 All States
opendata.utah.gov | Last Updated 2019-04-19T09:05:53.000ZRates Of Esophageal Cancer Per 100,000 All States
- API
Incidence Rate Of Non- Hodgkins Lymphoma Per 100,000 All States
opendata.utah.gov | Last Updated 2019-04-19T01:50:56.000ZIncidence Rate Of Non- Hodgkins Lymphoma Per 100,000 All States